secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001564590-23-003162
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics reports FY2022 net loss $101.1M; STK-001 shows 55% median seizure reduction
--------------------------------------------------------------------------------

- Net loss for FY2022 was $101.1M ($2.60/share) vs $85.8M ($2.34/share) in 2021; revenue of $12.4M from license agreement.
- STK-001 interim analysis: 55% median reduction in convulsive seizure frequency in 6 patients after multiple 45mg doses.
- Cash, equivalents, and marketable securities $230.2M at Dec 31, 2022; plus $44.7M raised since, extending runway to end of 2025.
- Data from multiple 45mg doses expected mid-2023; 70mg dose data in H2 2023; Phase 3 program planned for 2024.
- R&D expenses rose to $77.8M (FY2022) from $54.2M (FY2021) driven by STK-001 and STK-002 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000156459023003162/0001564590-23-003162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000156459023003162/stok-8k_20230306.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-003162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer